Management Team

Chen Schor President and Chief Executive Officer

Mr. Schor joined Synta as Executive Vice President and Chief Operating Officer in December 2014, and was named President and Chief Executive Officer and appointed to the Company’s Board of Directors in May 2015. Mr. Schor has over 15 years of leadership experience in biotechnology, medical devices, business development and private equity. Mr. Schor served as Vice President, Global Branded Products Business Development and Pipeline Management at Teva Pharmaceuticals and at leadership positions in several emerging private and public companies. Mr. Schor led licensing and M&A transactions valued at over $8 billion with GSK, Amgen, Pfizer, Merck KGaA, OncoGeneX and other companies. Mr. Schor was a Partner at Yozma Venture Capital where he led the foundation and growth of multiple therapeutic companies from inception to significant commercial success and exit. Mr. Schor holds a Master in Business Administration, a B.A. in Biology, a B.A. in Economics and is a Certified Public Accountant (CPA).[Back to Top]

Chen Schor

Marc R. Schneebaum Senior Vice President, Chief Financial Officer

Mr. Schneebaum joined Synta as Senior Vice President and Chief Financial Officer in December 2014. Mr. Schneebaum brings over 25 years of experience in the biotechnology and healthcare sector to Synta. Most recently, he has served as a consultant in the healthcare industry. From 2011 to 2013, Mr. Schneebaum served as President, Chief Executive Officer and a director of Predictive BioSciences, Inc., a commercial stage cancer diagnostics company. From 1997 to 2010, he served as President, Chief Executive Officer, and a director of Sensors for Medicine and Science, Inc., an emerging medical technology company. From 1991 to 1997, he served as Senior Vice President, Finance, Business Development and Administration, and Chief Financial Officer of Genetic Therapy, Inc., a biotechnology company (acquired by Sandoz/Novartis). From 1987 to 1991, Mr. Schneebaum was a Vice President at Alex Brown & Sons Incorporated, a leading investment banking firm (now part of Deutsche Bank), where he participated in a variety of finance and strategic assignments. Mr. Schneebaum began his career in the accounting and auditing group at KPMG LLP, advancing to Senior Manager in the management consulting group. Mr. Schneebaum has served as a director of GenVec, Inc., a publicly traded biopharmaceutical company, since 2007. Mr. Schneebaum received his degree in Business Administration from the University of Maryland and is a Certified Public Accountant (inactive).[Back to Top]

Marc R. Schneebaum

Vojo Vukovic, M.D., Ph.D. Senior Vice President, Chief Medical Officer

Dr. Vukovic joined Synta as Vice President, Clinical Research in January 2009. Dr. Vukovic has over 17 years experience in oncology drug development. Prior to Synta, he was Global Medical Lead for Sutent® and axitinib in a number of cancer indications at Pfizer. Prior to Pfizer, he served in key medical and regulatory roles at Aventis Pasteur, Ortho Biotech, ILEX Oncology, and BioNumerik Pharmaceuticals. Over the course of his career, Dr. Vukovic has been responsible for over 100 Phase 1 to Phase 4 clinical studies in cancer indications including melanoma, tumors of the lung, pancreas, breast, colorectal, ovarian, brain, as well as NHL and certain leukemias. Prior to his industry career, Dr. Vukovic was a post-doctoral fellow at the Ontario Cancer Institute, Toronto in Ontario and Institute for Cell Biology in Essen, Germany where he conducted basic and translational research in solid tumor microenvironments and oxidative stress. Dr. Vukovic received his Ph.D. and M.Sc. degrees from the University of Toronto and his M.D. degree from the University of Sarajevo, Bosnia and Herzegovina. [Back to Top]

Vojo Vukovic, M.D., Ph.D.

Wendy E. Rieder, Esq. Senior Vice President, General Counsel

Before joining Synta in December 2002, Ms. Rieder served as the co-founder, COO and VP, Business Development and Intellectual Property of Microbiotix, Inc., a privately-held biotechnology company developing small-molecule anti-infectives. She is a registered patent attorney with experience in all aspects of business and intellectual property law relating to private and public companies in the pharmaceutical and biotechnology industries. Ms. Rieder was also the VP, Business Development and Intellectual Property at CereMedix, Inc. and LipoGenics, Inc., a patent attorney at Boehringer Ingelheim Pharmaceuticals, and a patent agent at Fish & Neave. Ms. Rieder holds an M.S. in Organic Chemistry from Columbia University and a J.D. from Fordham University. [Back to Top]

Wendy E. Rieder, Esq.

Alan C. Rigby, Ph.D. Senior Vice President, Chief Scientific Officer

Dr. Rigby joined Synta as Chief Scientific Officer in September 2015. Dr. Rigby brings over 20 years of academic and industry experience in the areas of structural biology, computational drug discovery, and translational research of small and large molecules in oncology. Most recently, Dr. Rigby served as Vice President, Global Antibody Drug Conjugate Biology at the Lilly Oncology Research Laboratory at Eli Lilly and Company in New York. Prior to joining Eli Lilly in 2010, Alan was the Principal Investigator of a National Institutes of Health (NIH) funded independent academic laboratory and the Director of the Drug Discovery and Target Validation Program within the Center for Vascular Biology at the Beth Israel Deaconess Medical Center, Harvard Medical School. Dr. Rigby has served and continues to serve on national and international granting councils including the National Institutes of Health, National Science Foundation, Canadian Foundation for Innovation and Genome Quebec’s PRIVAC. He is the North American Editor for Current Computer Aided Drug Discovery and on the Editorial Advisory Board for Future Medicinal Chemistry. He has published more than 50 scientific papers, a book chapter and has more than 10 patents that have published or are pending. Dr. Rigby holds an Honors BSc. in Biochemistry and a Ph.D. in Biochemistry from the University of Western Ontario in Canada.[Back to Top]

Suresh R. Babu, Ph.D. Vice President, Drug Product Development

Before joining Synta in January 2006, Dr. Babu was employed at Pfizer Global R&D with responsibility for discovery formulation, preformulation, and formulation development. Prior to Pfizer, Dr. Babu worked for Johnson & Johnson identifying and implementing new technologies for drug delivery. Dr. Babu has extensive pharmaceutical industry experience in the areas of preformulation, enabling dosage forms, drug delivery, and the development of immediate and controlled release dosage forms. Dr. Babu has several years of teaching experience in Pharmaceutical Sciences. He earned his B.S. in Pharmacy (India) and Ph.D. in Pharmaceutics at the University of Connecticut, Storrs, Connecticut. Dr. Babu is a member of the Advisory Board of the School of Pharmacy at the University of Connecticut, Storrs, Connecticut. [Back to Top]

Suresh R. Babu, Ph.D.

Andrew J. Sonderfan, Ph.D., DABT Vice President, Drug Disposition and Preclinical Safety

Before joining Synta in December 2006, Dr. Sonderfan spent five years at Enanta Pharmaceuticals, Inc., during which time he served as Senior Director, Toxicology and Safety Pharmacology. From 2000 to 2001, Dr. Sonderfan was the Director of Toxicology and Product Safety at BioChem Pharma (today, Shire Pharmaceutical Development Inc.). Dr. Sonderfan began his industry career at Syntex, Inc. as Nonclinical Leader, Palonosetron Program. Dr. Sonderfan earned his B.S. in Toxicology from the Philadelphia College of Pharmacy and Science (today, the University of the Sciences in Philadelphia) and his Ph.D. in Toxicology from the University of Kansas Medical Center. [Back to Top]

Andrew J. Sonderfan, Ph.D., DABT

Sheila Wilson Vice President, Clinical Operations

Ms. Wilson has over 20 years of experience in the pharmaceutical industry and has held numerous leadership positions in Clinical Operations and Clinical Program Management at Pfizer and Vertex Pharmaceuticals, among others. Her most recent engagements have been in consulting for companies such as CoreRisks, Ltd., in regards to Clinical Quality efforts and Cubist Pharmaceuticals, in support of Clinical Operations Strategic Governance and Standards and Clinical Program Management. Ms. Wilson holds an MBA from St Joseph's University and a BSN from City University NY Lehman College. [Back to Top]

Sheila Wilson

Ilker Yalcin, Ph.D., M.B.A. Vice President, Biostatistics and Data Management

Prior to joining Synta in May 2011, Dr. Ilker Yalcin was Research Advisor/Group Leader of the Global Oncology Business Unit at Eli Lilly and Company where he was responsible for helping design innovative clinical trials, leading development of multiple oncology compounds, performing pharmacogenetics analyses and managing a team of statisticians. Over his 15 year tenure at Eli Lilly, Dr. Yalcin held increasingly senior leadership positions including Director – Statistics, where he managed the statistical team in Endocrine, Oncology, Women’s Health, Urology, Reproductive Medicine, Cardiovascular and Critical Care in Lilly USA. Prior to joining Eli Lilly, Dr. Yalcin served as Biostatistician/Epidemiologist for the World Health Organization, Division of Mental Health in Geneva, Switzerland. Dr. Yalcin received his Ph.D. in Statistics from Iowa State University, and his M.B.A. from Indiana University, Kelly School of Business. [Back to Top]

Ilker Yalcin, Ph.D., M.B.A.

Weiwen Ying, Ph.D. Vice President, Discovery Chemistry

Dr. Ying joined Shionogi BioResearch Corporation in September 2000, which became part of Synta Pharmaceuticals Corp in September 2002. He initiated and championed the discovery and development of ganetespib, our lead oncology candidate, and is a co-inventor of the HDC technology and leading our discovery efforts in the HDC program. Dr. Ying has published >20 peer-review journal articles and also has >70 issued or pending patents. Prior to joining Synta in 2000, Dr. Ying was a postdoctoral fellow at SUNY Stony Brook and Yale University. He obtained Ph.D. in Organic Chemistry from Clemson University and M.S. from Shanghai Institute of Organic Chemistry, Chinese Academy of Science.[Back to Top]

Weiwen Ying, Ph.D.

David Noskowitz Senior Director, Regulatory Affairs

Mr. Noskowitz joined Synta in March 2005. Prior to joining Synta, Mr. Noskowitz was Director of Regulatory Affairs at Genzyme Corporation, where his efforts contributed to U.S., E.U., and international approvals of Aldurazyme(R) (laronidase), a treatment for Mucopolysaccharidosis I (MPS I). While at Genzyme, Mr. Noskowitz served as team leader for interdisciplinary project teams and provided regulatory perspective on in-licensing/acquisition due diligence activities. Prior to joining Genzyme in 2000, Mr. Noskowitz was Associate Director and Manager of Regulatory Affairs at Wyeth-Ayerst Research/Genetics Institute, Inc. Prior to that, Mr. Noskowitz served as Regulatory Affairs Manager at Bristol-Myers Squibb. Mr. Noskowitz received an M.Eng. degree in Chemical Engineering from the University of Virginia in Charlottesville, and earned both a B.S. in Environmental Engineering and a B.A. in Chemistry at the University of Rochester.[Back to Top]

David Noskowitz

Dinesh Chimmanamada, Ph.D. Director, Oncology Discovery

Dr. Chimmanamada joined Synta in November 2002. He is a co-inventor of the HDC technology and has been instrumental in the company’s work with its lead HDC candidates and other oncology discovery efforts such as Hsp90 inhibitors and IL-12 production inhibitors. Dr. Chimmanamada has published >18 peer-review journal articles and also has >24 issued or pending patents. Prior to joining Synta in 2002, Dr. Chimmanamada was a postdoctoral fellow at UMass Medical School, Worcester. He obtained Ph.D. in Organic Chemistry from National Chemical Laboratory in Pune, India and M.Sc. from Mangalore University, Mangalore, India.[Back to Top]

Dinesh Chimmanamada, Ph.D.